Retrieve available abstracts of 38 articles: HTML format
Single Articles
June 2025
STANGE C, Dreyer TF, Riedel M, Elsen F, et al PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl
peptidase 4 (DPP4) in ovarian cancer.
Br J Cancer. 2025 Jun 27. doi: 10.1038/s41416-025-03076. PubMedAbstract available
LIU Y, Chen Z, Duan Y, Shao Z, et al Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the
malignant progression of ovarian cancer.
Br J Cancer. 2025 Jun 24. doi: 10.1038/s41416-025-03079. PubMedAbstract available
NARAYANAN B, Buddenkotte T, Smith H, Shah M, et al Growth kinetics of high-grade serous ovarian cancer: implications for early
detection.
Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03082. PubMedAbstract available
May 2025
SCHIEMER R, Grant J, Shafiee MN, Phang S, et al Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer
detection.
Br J Cancer. 2025 May 18. doi: 10.1038/s41416-025-03050. PubMedAbstract available
TYRAKIS PA, Kampjut D, Steele GF, Lindstrom HJG, et al Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the
PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
Br J Cancer. 2025 May 13. doi: 10.1038/s41416-025-03035. PubMedAbstract available
April 2025
TREWIN-NYBRATEN CB, Leithe S, Paulsen T, Langseth H, et al Ovarian cancer survival by residual disease following cytoreductive surgery: a
nationwide study in Norway.
Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03018. PubMedAbstract available
LAGA T, Van Rompuy AS, Busschaert P, Marquina G, et al Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.
Br J Cancer. 2025 Apr 23. doi: 10.1038/s41416-025-03012. PubMedAbstract available
SU H, Jin X, Kong L, You Y, et al The triage role of cytological DNA methylation in women with non-16/18,
specifically genotyping high-risk HPV infection.
Br J Cancer. 2025 Apr 10. doi: 10.1038/s41416-025-03005. PubMedAbstract available
March 2025
PIGNATA S, Oza A, Hall G, Pardo B, et al Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian
cancer by somatic or germline BRCA and homologous recombination repair mutation
status.
Br J Cancer. 2025 Mar 17. doi: 10.1038/s41416-025-02966. PubMedAbstract available
YE X, Zheng J, Hu D, Liu L, et al Identification of increased dedifferentiation along the Prom1+ cancer cells in
Mullerian adenosarcoma with sarcomatous overgrowth.
Br J Cancer. 2025;132:438-449. PubMedAbstract available
December 2024
MERRITT MA, Abe SK, Islam MR, Rahman MS, et al Reproductive factors and risk of epithelial ovarian cancer: results from the Asia
Cohort Consortium.
Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02924. PubMedAbstract available
LIU C, Reger M, Fan H, Wang J, et al Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the
prostate, lung, colorectal, and ovarian cancer screening trial.
Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929. PubMedAbstract available
XU Q, Kowalski J Non-B DNA-informed mutation burden as a marker of treatment response and outcome
in cancer.
Br J Cancer. 2024;131:1825-1832. PubMedAbstract available
November 2024
MORGAN RD, Wang X, Barnes BM, Spurgeon L, et al Germline BRCA1/2 status and chemotherapy response score in high-grade serous
ovarian cancer.
Br J Cancer. 2024 Nov 16. doi: 10.1038/s41416-024-02874. PubMedAbstract available
TAN R, Wen M, Yang W, Zhan D, et al Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular
subtype-associated cell landscapes and immunotherapy targets.
Br J Cancer. 2024 Nov 15. doi: 10.1038/s41416-024-02894. PubMedAbstract available
ZAHID MU, Waguespack M, Harman RC, Kercher EM, et al Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an
integrated mathematical and in vitro study.
Br J Cancer. 2024;131:1378-1386. PubMedAbstract available
October 2024
HIRAHARA Y, Shimizu K, Yamasaki S, Iyoda T, et al Crucial immunological roles of the invasion front in innate and adaptive immunity
in cervical cancer.
Br J Cancer. 2024 Oct 29. doi: 10.1038/s41416-024-02877. PubMedAbstract available
SUN Y, Yin Z, Li S, Wu L, et al Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to
overcome resistance to chemo-immunotherapy in ovarian cancer.
Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02863. PubMedAbstract available
September 2024
YANG X, Wu Y, Ficorella L, Wilcox N, et al Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk
prediction in UK Biobank.
Br J Cancer. 2024 Sep 18. doi: 10.1038/s41416-024-02851. PubMedAbstract available
KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al PARP inhibition with rucaparib alone followed by combination with atezolizumab:
Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative
breast cancers.
Br J Cancer. 2024;131:820-831. PubMedAbstract available
SMITH HL, Willmore E, Prendergast L, Curtin NJ, et al ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to
induce synthetic lethality with PARP inhibitors.
Br J Cancer. 2024;131:905-917. PubMedAbstract available
SUVAAL I, Hummel SB, Mens JM, Tuijnman-Raasveld CC, et al Efficacy of a nurse-led sexual rehabilitation intervention for women with
gynaecological cancers receiving radiotherapy: results of a randomised trial.
Br J Cancer. 2024;131:808-819. PubMedAbstract available
August 2024
TAKAMATSU S, Hillman RT, Yoshihara K, Baba T, et al Molecular classification of ovarian high-grade serous/endometrioid carcinomas
through multi-omics analysis: JGOG3025-TR2 study.
Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02837. PubMedAbstract available
ZHUO L, Meng F, Sun K, Zhou M, et al Integrated immuno-transcriptomic analysis of ovarian cancer identifies a
four-chemokine-dominated subtype with antitumor immune-active phenotype and
favorable prognosis.
Br J Cancer. 2024 Aug 2. doi: 10.1038/s41416-024-02803. PubMedAbstract available
July 2024
NAGLE CM, Ibiebele TI, Bandera EV, Cramer D, et al Pre-diagnosis tea and coffee consumption and survival after a diagnosis of
ovarian cancer: results from the Ovarian Cancer Association Consortium.
Br J Cancer. 2024 Jul 18. doi: 10.1038/s41416-024-02792. PubMedAbstract available
June 2024
ARONSON SL, Walker C, Thijssen B, van de Vijver KK, et al Tumour microenvironment characterisation to stratify patients for hyperthermic
intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02731. PubMedAbstract available
QIU L, Li R, Wang Y, Lu Z, et al PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly
(ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex.
Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02749. PubMedAbstract available
May 2024
STOER NC, Vangen S, Singh D, Fortner RT, et al Menopausal hormone therapy and breast cancer risk: a population-based cohort
study of 1.3 million women in Norway.
Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590. PubMedAbstract available
KENKHUIS MF, Stelten S, Hartman YA, Brouwer CG, et al Effects of a combined exercise and dietary intervention on body composition,
physical functioning and fatigue in patients with ovarian cancer: results of the
PADOVA trial.
Br J Cancer. 2024 May 8. doi: 10.1038/s41416-024-02694. PubMedAbstract available
HERMAN L, Amo A, Legois B, Di Carlo C, et al A cellular model provides insights into the pathogenicity of the oncogenic FOXL2
somatic variant p.Cys134Trp.
Br J Cancer. 2024;130:1453-1462. PubMedAbstract available
REBOLJ M, Brentnall AR, Cuschieri K Predictable changes in the accuracy of human papillomavirus tests after
vaccination: review with implications for performance monitoring in cervical
screening.
Br J Cancer. 2024;130:1733-1743. PubMedAbstract available
NG CW, Tsang YTM, Gershenson DM, Wong KK, et al The prognostic value of MEK pathway-associated estrogen receptor signaling
activity for female cancers.
Br J Cancer. 2024;130:1875-1884. PubMedAbstract available
April 2024
DHAR C, Ramachandran P, Xu G, Pickering C, et al Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic
profiling.
Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644. PubMedAbstract available
PORTNOY A, Pedersen K, Kim JJ, Burger EA, et al Vaccination and screening strategies to accelerate cervical cancer elimination in
Norway: a model-based analysis.
Br J Cancer. 2024 Apr 20. doi: 10.1038/s41416-024-02682. PubMedAbstract available
KMENT J, Newsted D, Young S, Vermeulen MC, et al Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical
ovarian cancer models by promoting T effector and NK cell responses.
Br J Cancer. 2024 Apr 15. doi: 10.1038/s41416-024-02677. PubMedAbstract available
TIAN Y, Lin Y, Qu C, Arndt V, et al Genetic risk impacts the association of menopausal hormone therapy with
colorectal cancer risk.
Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638. PubMedAbstract available
March 2024
ROQUE DM, Siegel ER, Buza N, Bellone S, et al Correction: Randomised phase II trial of weekly ixabepilone +/- biweekly
bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary
peritoneal cancer.
Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02628. PubMed
MATOBA Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, et al Targeting Galectin 3 illuminates its contributions to the pathology of uterine
serous carcinoma.
Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02621. PubMedAbstract available